Insulin-lowering therapeutic modalities for polycystic ovary syndrome

Endocrinol Metab Clin North Am. 1999 Jun;28(2):423-38, viii. doi: 10.1016/s0889-8529(05)70078-5.

Abstract

This article summarizes the relationship between insulin and androgen excess, with a focus on what is known regarding two related issues in polycystic ovary syndrome: (1) defects in insulin secretion in PCOS and their role in the development of glucose intolerance in this population; and (2) pharmacologic interventions designed to attenuate hyperinsulinemia and its sequelae in PCOS.

Publication types

  • Review

MeSH terms

  • Female
  • Glucose Intolerance / etiology
  • Humans
  • Hyperinsulinism / drug therapy*
  • Hyperinsulinism / etiology
  • Hypoglycemic Agents / therapeutic use
  • Insulin / metabolism
  • Insulin Secretion
  • Metformin / therapeutic use
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology

Substances

  • Hypoglycemic Agents
  • Insulin
  • Metformin